Zarontin Capsule
NDC Package 0071-0237-24

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Zarontin (ethosuximide) capsules is a medication used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). This formulation utilizes a capsule delivery system. Marketed by Parke-davis Div Of Pfizer Inc, this product is identified by NDC 0071-0237 and is authorized under FDA application NDA012380.

Identification & Billing

NDC Package Code
0071-0237-24
Package Description
100 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
00071023724
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zarontin
Non-Proprietary Name
Ethosuximide
Substance Name
Ethosuximide
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
This medication is used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Regulatory & Marketing

Labeler Name
Parke-davis Div Of Pfizer Inc
Product Type
Human Prescription Drug
FDA Application #
NDA012380
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-22-2000
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0071-0237-24 identifies a specific commercial package of 100 capsule in 1 bottle of Zarontin, a human prescription drug labeled by Parke-davis Div Of Pfizer Inc. This capsule is formulated for oral use and contains ethosuximide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Parke-davis Div Of Pfizer Inc on September 22, 2000. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

How is this Parke-davis Div Of Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00071023724. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0071-0237-24
11-Digit CMS (5-4-2)
00071-0237-24

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.